Stocks
Alnylam Pharmaceuticals (ALNY) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -13.1 | -18.5 | -28.2 | -30.3 | -93.5 | -147.5 | ||
| Changes by years, y/y, % | +74% | +41% | +53% | +7% | +209% | +65.6% | |||
Alnylam Pharmaceuticals. EV/EBITDA
Alnylam Pharmaceuticals. EV/EBITDA, changes, %
Alnylam Pharmaceuticals (ALNY) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EV/EBITDA | ? | -57.0 | -85.1 | -122.1 | 248.3 | -259.0 | -147.5 | |
| Changes by years, y/y, % | +81% | +116% | +267% | -965% | +354% | |||
| Changes by quarters, q/q, % | +99% | +49% | +44% | -303% | -204% | |||
